Homepage Top Section2

The funding round was spearheaded by existing investors Engine Ventures and Safar Partners, with new participations from Bill Gates, Parkinson’s UK, and the Michael J. Fox Foundation, which

Under the terms of the agreement, RevolKa will utilise its protein engineering platform, aiProtein, integrated with artificial intelligence (AI), to create and deliver highly functional proteins. The companies

Denosumab has secured approval in several countries and regions under different trade names for a range of several indications such as for osteoporosis treatment in postmenopausal women who

NfX Bio led the financing which will bolster the company’s development of programmable ribonucleic acid (RNA)-based therapeutics utilising molecular RNA sensors for precise drug delivery. The funding round

The product, which received approval from the US Food and Drug Administration in April 2024, is now available for direct distribution to states and municipalities nationwide. Naloxone HCI

The company said it aims to achieve this target by registering growth in its current portfolio in biopharmaceuticals, oncology, and rare diseases.  The effort also includes the launch

This marks the first biosimilar launched under the strategic partnership between the two companies. SIMLANDI has been approved by the US Food and Drug Administration (FDA) as the

With this agreement, IRBM will be able to leverage CRISPR/Cas9 technology to advance its drug discovery processes. The editing technology will also be integrated into the comprehensive drug

TWYNEO is claimed to be the first and only US Food and Drug Administration (FDA)-approved fixed-dose cream which combines tretinoin and benzoyl peroxide for treating acne vulgaris in